Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Int J Clin Oncol. 2019 Sep;24(9):1111-1118. doi: 10.1007/s10147-019-01449-3. Epub 2019 Apr 15.
The purpose of this study was to evaluate the real world situation and clarify the problem in initial treatment for elderly patients with ovarian cancer in Japan.
We used the ovarian cancer database, containing all patients diagnosed and treated with International Federation of Gynecology and Obstetrics Stage I-IV ovarian cancer at the National Cancer Center Hospital in Japan from June 2008 to April 2013. Patients were stratified into two groups based on age: an elderly group, aged 70 years or older, and a younger group, aged below 70 years. We retrospectively assessed the rate of receiving standard therapy, and the feasibility and safety of chemotherapy compared with younger patients.
In total, 244 patients (elderly group, 36 patients; younger group, 208 patients) were analyzed. A significantly lower proportion of elderly patients than younger patients received standard therapy (15.7% vs. 32.5%, p = 0.026). Even for the elderly group, 95% patients underwent surgery in our institution. Conversely the rate of patients receiving nonstandard chemotherapy in the elderly group was significantly higher than in the younger group (30.5% vs. 9.6%, p = 0.01).
This study clarified the type of treatment being performed in the field, and the proportion of elderly ovarian cancer patients receiving standard therapy compared with younger patients in Japan. In addition, the actual situation of elderly patients in Japan might be different from that in Western countries. We need to evaluate the appropriate treatment for elderly patients in Japan.
本研究旨在评估日本老年卵巢癌患者初始治疗的实际情况并阐明其中存在的问题。
我们使用卵巢癌数据库，该数据库包含了 2008 年 6 月至 2013 年 4 月在日本国家癌症中心医院诊断和治疗国际妇产科联合会（FIGO）Ⅰ-Ⅳ期卵巢癌的所有患者。根据年龄将患者分为两组：老年组，年龄≥70 岁；年轻组，年龄＜70 岁。我们回顾性评估了两组患者接受标准治疗的比例，以及与年轻患者相比化疗的可行性和安全性。
共分析了 244 例患者（老年组 36 例，年轻组 208 例）。老年组患者接受标准治疗的比例明显低于年轻组（15.7% vs. 32.5%，p=0.026）。即使是老年组，也有 95%的患者在我院接受了手术。相反，老年组接受非标准化疗的患者比例明显高于年轻组（30.5% vs. 9.6%，p=0.01）。
本研究阐明了日本当前开展的治疗类型，以及与年轻患者相比老年卵巢癌患者接受标准治疗的比例。此外，日本老年患者的实际情况可能与西方国家不同。我们需要评估日本老年患者的适宜治疗方案。
